ResearchPod Summary
Recent studies have shown that P-selectin glycoprotein ligand-1 (PSGL-1), a mucin-like protein, restricts HIV-1 by becoming incorporated into virions and sterically hindering their attachment to target cells. Researchers sought to determine whether other cell-surface proteins sharing similar structural characteristics—specifically, a heavily glycosylated and extended extracellular domain—also function as antiviral factors. The team examined a group of ten proteins, including CD43, CD34, TIM-1, PODXL1, PODXL2, CD164, MUC1, MUC4, and TMEM123. They collectively labeled this group the Surface-Hinged, Rigidly-Extended Killer (SHREK) family.
To evaluate these proteins, the authors co-transfected HEK293T cells with HIV-1 DNA and expression vectors for individual SHREK proteins. They then analyzed the released virions for infectivity in indicator cell lines, measured their physical incorporation into viral particles, and tested their ability to block virus-cell attachment. Finally, they assessed whether these proteins exhibit broad-spectrum antiviral activity by testing their impact on influenza A and a SARS-CoV-2 virus-like particle (VLP).
All tested SHREK proteins inhibited HIV-1 infectivity in a dose-dependent manner. The primary mechanism of action for most SHREKs was consistent with PSGL-1: they are incorporated into the viral envelope during assembly and subsequently block the virion from attaching to the target cell membrane. Notably, CD34, a common marker for stem and progenitor cells, emerged as the most potent inhibitor of HIV-1 in this set.
Beyond HIV-1, the SHREK family displayed broad-spectrum activity. Each protein successfully inhibited the infectivity of influenza A virions. However, the efficacy against a hybrid SARS-CoV-2 VLP was more selective; while a subset of SHREKs (including PSGL-1, CD164, TIM-1, MUC1, and MUC4) inhibited the SARS-CoV-2 VLP, others that were highly effective against HIV-1 showed no significant impact. The authors suggest that these differences likely stem from distinct viral budding pathways—HIV-1 buds from the plasma membrane, whereas SARS-CoV-2 buds from internal membranes—which may determine which surface proteins are incorporated into the maturing virion.
This research identifies SHREK proteins as a previously underappreciated layer of the host innate immune system capable of defending against diverse enveloped viruses. By understanding how these proteins sterically interfere with viral entry, researchers may be able to develop new therapeutic strategies that boost SHREK expression or disrupt viral counter-defenses, potentially offering a broad-spectrum approach to antiviral intervention.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.